Author

Jay Tuttle 1

1 Eli Lilly and Company,Indianapolis,United States

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

Marc Ferrante, William Sandborn, Bal R Bandhari, Geert D’Haens, Brian G. Feagan, Michael Durante, Vipin Arora, Jay Tuttle, April Naegeli

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB (LY3074828) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN A PHASE 2 STUDY

William Sandborn, Geert R. D'Haens, Marc Ferrante, Raj Bhandari, Elina Berliba, Brian G. Feagan, Janelle Laskowski, Stuart Friedrich, Jay Tuttle, Michael Durante

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

William Sandborn, Marc Ferrante, Bal R. Bhandari, Geert R. D'Haens, Elina Berliba, Brian G. Feagan, Paul Klekotka, Janelle Laskowski, Michael Durante, Jay Tuttle, April Naegeli

Histologic remission and mucosal healing in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

Rish K. Pai, James Canavan, Jay Tuttle, Michael Durante, Vipin Arora, Catherine Milch, Noam Harpaz, Geert D’Haens, Bruce E. Sands, William Sandborn

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

Item 1 - 8 / 8
1